The plain-language read
Effective in skin types IV–VI where hydroquinone carries elevated risks.
- AzA produces comparable melasma response to HQ 4% over 24 weeks
- No ochronosis risk — safe for long-term use
- Active in skin types IV–VI without inducing PIH
- Adjunctive benefit for acne and rosacea (anti-inflammatory)
First-choice brightener for Fitzpatrick IV–VI. Tolerable with retinoids and vitamin C in evening protocols. Pregnancy-safe (Category B).
What this means for your routine
If you're targeting melasma, this research supports adding azelaic acid to your AM/PM routine. Effective concentration range: 4% based on this study. Timeline to expect: 24 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
Technical Summary, For Professional Reference
Clinical context
AzA 20% cream and 15% gel produce melasma improvement comparable to HQ 4% at 24 weeks across multiple trials. Mechanisms: competitive tyrosinase inhibition, mitochondrial enzyme interference, anti-keratinizing effect. Especially valuable in Fitzpatrick IV–VI where HQ-induced ochronosis is a concern.
Full abstract→
Azelaic acid (AzA) is a dicarboxylic acid with tyrosinase-inhibiting, antioxidant, and anti-inflammatory activity. Multiple controlled trials demonstrate efficacy comparable to hydroquinone 4% in melasma at 24 weeks, with superior safety profile and no ochronosis risk. Effective in skin types IV–VI where hydroquinone carries elevated risks.
Original source →Multitargeted Modulation of Skin Dullness by HNHT Formulation: Synergistic Inhibition of Melanogenesis, Glycation, and Lipofuscin Deposition.
Skin dullness, characterized by pigmentation disorders and yellowing, is a major cosmetic concern in Asian populations. Lipofuscin exhibits ultraviolet (UV)/visible light spectral absorption, reduces skin reflectance, and contributes to dullness, whereas existing therapies targeting melanogenesis and glycation lack comprehensive efficacy. This study aimed to evaluate the multimodal anti-dullness effects of a novel formulation (HNHT: hyaluronic acid, niacinamide, hydrolyzed red algae, and tranexamic acid).
Hyaluronic acid-based skin booster with glutathione combined with 1064-nm Nd:YAG laser and oral tranexamic acid for melasma: A prospective comparative study.
Melasma is a chronic, acquired facial hyperpigmentation disorder with multifactorial pathogenesis and frequent relapse. Low-fluence 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) (LQSNY) laser with oral tranexamic acid (TA) is widely used, but responses are often incomplete and short-lived. glutathione (GSH), an antioxidant that inhibits melanogenesis, may improve outcomes when delivered intradermally with a hyaluronic acid (HA) carrier.
Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial.
smsamani@sums. Melasma is a common hyperpigmentary skin disorder. Because of its high prevalence and serious complications, including negative psychiatric effects, early diagnosis and treatment would be essential.